title: 2004 drug approval highlights: FDA update.
authors.affiliation: Regis University, Denver, CO, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Laustsen
authors.forename: Lynn
authors.initials: L
authors.lastname: Wimmett
mesh_terms: D000279:Administration, Cutaneous; D017311:Amlodipine / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000928:Antidepressive Agents / Q000494:pharmacology; D001993:Bronchodilator Agents / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D017277:Drug Approval; D004338:Drug Combinations; D000068736:Duloxetine Hydrochloride; D000077545:Eplerenone; D004958:Estradiol / Q000008:administration & dosage*; D018691:Excitatory Amino Acid Antagonists; D005260:Female; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006538:Heptanoic Acids / Q000494:pharmacology; D006801:Humans; D048628:Ketolides / Q000494:pharmacology; D008297:Male; D008559:Memantine / Q000494:pharmacology*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D011758:Pyrroles / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology; D000078262:Rifaximin; D012602:Scopolamine Derivatives / Q000494:pharmacology*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology*; D000069447:Tiotropium Bromide; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D000928:Antidepressive Agents; D001993:Bronchodilator Agents; D002317:Cardiovascular Agents; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists; D005765:Gastrointestinal Agents; D006538:Heptanoic Acids; D048628:Ketolides; D011758:Pyrroles; D012294:Rifamycins; D012602:Scopolamine Derivatives; D013876:Thiophenes; C487936:amlodipine, atorvastatin drug combination; D017311:Amlodipine; D013148:Spironolactone; D004958:Estradiol; D000077545:Eplerenone; D000068736:Duloxetine Hydrochloride; C106791:telithromycin; D000078262:Rifaximin; D008559:Memantine; D000069447:Tiotropium Bromide